RBQM Maturity Model Unlocking RBQM Success: Insights, Trends & Strategies for Smarter Clinical Trials
Hosted by CluePoints and Tufts CSDD, this on-demand webinar takes a deep dive into the current state of Risk-Based Quality Management (RBQM) across the clinical trial landscape.
Based on a recent global survey of 119 pharmaceutical and biotechnology companies conducted by Tufts CSDD, the session explores RBQM implementation through the lens of a new maturity model,highlighting traits and challenges across four key groups: Innovators, Early Adopters, Early Majority, and Resisters. Where do you fall on the spectrum? How about your peers? Now’s your chance to find out.
Attendees gained practical insights into the impact of ICH E6 R3 on RBQM strategies, adoption trends by company size and segment, the components seeing the highest and lowest levels of implementation, and actionable strategies to overcome common barriers and advance organizational maturity.
Hosted by CluePoints and Tufts CSDD, this on-demand webinar takes a deep dive into the current state of Risk-Based Quality Management (RBQM) across the clinical trial landscape.
Based on a recent global survey of 119 pharmaceutical and biotechnology companies conducted by Tufts CSDD, the session explores RBQM implementation through the lens of a new maturity model, highlighting traits and challenges across four key groups: Innovators, Early Adopters, Early Majority, and Resisters. Where do you fall on the spectrum? How about your peers? Now’s your chance to find out.
Attendees gained practical insights into the impact of ICH E6 R3 on RBQM strategies, adoption trends by company size and segment, the components seeing the highest and lowest levels of implementation, and actionable strategies to overcome common barriers and advance organizational maturity.
